Dasatinib Use and Risk of Cytomegalovirus Reactivation After Allogeneic Hematopoietic-Cell Transplantation.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 28419210.
- Also identified by DOI 10.1093/cid/cix325.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Viral infections have been reported with dasatinib use, but its cytomegalovirus risk after hematopoietic-cell transplantation (HCT) is not known. We found that post-HCT dasatinib use increased the risk of cytomegalovirus reactivation (adjusted hazard ratio, 7.65; 95% confidence interval, 1.84-31.7), controlling for acute graft-versus-host disease, in 109 patients with Philadelphia-chromosome-positive malignancies.
Medical subject headings
- Antineoplastic Agents
- Cytomegalovirus
- Cytomegalovirus Infections
- Dasatinib
- Hematopoietic Stem Cell Transplantation